US Representative

Gus Bilirakis 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 11)

Legislative Session

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3950

Introduced
6/9/23  
Refer
6/9/23  
Refer
6/16/23  
Report Pass
12/6/23  
Transparency In Charges for Key Events Ticketing Act TICKET Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4011

Introduced
6/12/23  
Refer
6/12/23  
TACT Act of 2023 Timely Access to Clinical Treatment Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4056

Introduced
6/13/23  
Refer
6/13/23  
Ensuring Medicaid Continuity for Children in Foster Care Act of 2023

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4063

Introduced
6/13/23  
Refer
6/13/23  
FIND Fentanyl Act of 2023 Federal Interventions and New Detections of Fentanyl Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB407

Introduced
1/20/23  
Refer
1/20/23  
Protect the UNBORN (Undo the Negligent Biden Orders Right Now) Act or the Protect the UNBORN Act This bill prohibits federal implementation of and funding for specified executive orders that address access to reproductive health care services, including services related to pregnancy or the termination of a pregnancy.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4076

Introduced
6/13/23  
Refer
6/13/23  
United States-Israel Health Technologies Cooperation Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB41

Introduced
1/9/23  
Refer
1/9/23  
VA Same-Day Scheduling Act of 2023 This bill requires the Department of Veterans Affairs (VA) to ensure that when a veteran enrolled in the VA health care system contacts the VA by telephone to schedule an appointment for care or services at a VA facility, the scheduling for the appointment occurs during that telephone call.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4104

Introduced
6/14/23  
Refer
6/14/23  
Preserving Patient Access to Home Infusion Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4132

Introduced
6/14/23  
Refer
6/14/23  
Report Pass
6/21/23  
Falun Gong Protection Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4157

Introduced
6/15/23  
Refer
6/15/23  
Not Just a Number Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4167

Introduced
6/15/23  
Refer
6/15/23  
Refer
6/16/23  
Protecting America’s Distribution Transformer Supply Chain Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4181

Introduced
6/7/23  
To designate the area between the intersections of International Drive, Northwest and Van Ness Street, Northwest and International Drive, Northwest and International Place, Northwest in Washington, District of Columbia, as "Tiananmen Square Memorial Boulevard", and for other purposes.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4261

Introduced
6/21/23  
Refer
6/21/23  
ARC Act of 2023 Amputation Reduction and Compassion Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4264

Introduced
6/21/23  
Reducing Exposure to Burn Pits Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)